Driving small molecule antiviral development for Respiratory Syncytial Virus infection

RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: RV521

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial

Meet the Team...
Latest News
Virologist Position (Durham Area)

ReViral are currently recruiting a Virologist to join our laboratory team based in the Durham area, UK, to support the company's antiviral drug discovery and development...

Virologist Position (Stevenage)

ReViral are currently recruiting a Virologist to join our laboratory team based in Stevenage, UK.

This is a practical laboratory-based position and we are looking for...

ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

London, UK, 26th February 2019: ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial...

Contact us...
Privacy Policy